Contrast agent preparation equipment, preparation method and contrast agent
The toxicity and applicability of Gd contrast agents are solved by using nitric oxide or carbon monoxide gas treatment agent to produce methoglobin or carbooxyhemoglobin contrast agents to ex vivo blood, providing a safe and efficient alternative for a wide range of Magnetic resonance angiography.
Patent Information
- Application Number
- CN202310573160.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-22
- Publication Date
- 2024-11-22
AI Technical Summary
The existing magnetic resonance angiography agent Gd has the risk of hepatotoxicity, nephrotoxicity and potential nerve damage, and is not applicable to patients with blood-brain barrier damage and high vascular permeability, which limits its wider clinical application.
A contrast agent preparation equipment and method are provided to treat ex vivo blood using nitric oxide or carbon monoxide gas treatment agent to generate methoglobin or carbooxyhemoglobin as contrast agent, avoiding the risk of liver and kidney metabolism and nerve damage.
The prepared methhemoglobin or carbooxyhemoglobin contrast agent is not hepatotoxic or nephrotoxic, will not be deposited in the brain, is highly safe, is suitable for a wide range of clinical applications, is highly efficient, and can quickly obtain contrast agents that meet clinical needs.
Smart Images

Figure CN118987285A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medical contrast imaging, and in particular relates to a contrast agent preparation device, a preparation method and a contrast agent. Background Art
[0002] Magnetic resonance imaging (MRI) is an examination technique based on the principle that atomic nuclei with magnetic moments can produce energy level transitions under the action of a magnetic field. It is of great value in diagnosing degenerative diseases. Compared with CT and PET, MRI has the advantages of being non-radioactive and not causing cell mutations and thus tumors. MRI is mainly based on T1 relaxation, T2 relaxation and T2* relaxation imaging.
[0003] Magnetic resonance angiography (MRA) is a non-invasive diagnostic method. It combines magnetic resonance technology with intravenous contrast agents to display blood vessels. The contrast agent makes the blood vessels appear opaque on the MRI image, allowing doctors to see the blood vessels being evaluated. MRA is commonly used to examine the heart and other soft tissues and evaluate blood flow. In recent years, it has also been expanded to evaluate stroke, tumors, etc.
[0004] The commonly used contrast agent for MRA is Gd (gadolinium, element 64), which is a heavy metal that is mainly metabolized by the liver and kidneys. It has hepatotoxicity and nephrotoxicity. It needs to be used very cautiously in clinical practice, which limits the wider clinical use of MRA. At the same time, for patients with damaged blood-brain barrier, such as hemorrhagic stroke, concussion, brain fog, Alzheimer's disease, Huntington's disease, multiple sclerosis, autism and other neurological diseases, Gd will remain in the brain, potentially causing nerve damage. In addition, for patients with high vascular permeability organs, Gd will also leak from blood vessels into organ tissues, causing health hazards.
[0005] Therefore, it is necessary to provide a contrast agent that can replace Gd for use in MRA so as to overcome the problems that may exist when using Gd as a contrast agent and at the same time meet the requirements of high safety and wide application range. Summary of the invention
[0006] In order to solve at least one of the above technical problems, according to one aspect of the present invention, a contrast agent preparation device is provided, comprising: A treatment agent module, used for providing a gas treatment agent containing nitric oxide or carbon monoxide required for preparing a contrast agent; The blood processing module is used to process the collected ex-vivo blood using a processing agent.
[0007] According to the contrast agent preparation device of an embodiment of the present invention, optionally, the processing agent module includes: A gas supply device for pre-storing or instant preparation of gas containing nitric oxide or carbon monoxide; An output pipeline connected to the gas supply device to output the gas containing nitric oxide or carbon monoxide; The flow controller is arranged on the output pipeline and is used to control the output flow of the gas.
[0008] According to the contrast agent preparation device of the embodiment of the present invention, optionally, the gas supply device is a nitric oxide supply device, comprising: A reaction chamber, a reaction medium contained in the reaction chamber, a plurality of electrodes arranged in the reaction medium, a carrier gas inlet for introducing a carrier gas into the reaction medium, a gas outlet for outputting a product gas, and an energy source acting on the plurality of electrodes.
[0009] According to the contrast agent preparation device of an embodiment of the present invention, optionally, the blood processing module includes: A blood container, which is used to hold the collected ex-vivo blood, and the blood container is configured to receive the nitric oxide-containing gas transmitted by the output pipeline; A vibrating member is used for accommodating a blood container, wherein the vibrating member is configured to vibrate the blood container.
[0010] According to the contrast agent preparation device of an embodiment of the present invention, optionally, the blood processing module further includes: A purge member, one end of which is connected to the output pipeline of the treatment agent module and the other end of which is located above the ex vivo blood; The blood treatment module is configured to allow the nitric oxide-containing gas treatment agent to be swept from above the ex vivo blood, while the vibration element applies vibration to the ex vivo blood, so that the ex vivo blood contacts the nitric oxide-containing gas treatment agent.
[0011] According to the contrast agent preparation device of an embodiment of the present invention, optionally, the blood processing module is configured to, after pre-supplementing a sufficient amount of nitric oxide-containing gas treatment agent into the blood container, apply vibration to the ex vivo blood by the vibrator so that the ex vivo blood contacts the nitric oxide-containing gas treatment agent.
[0012] According to one aspect of the present invention, there is provided a method for preparing a contrast agent, comprising the following steps: Collecting blood from the body; Providing a gas treatment agent containing nitric oxide or carbon monoxide required for preparing a contrast agent; Treating the collected blood with a nitric oxide-containing gas treatment agent until the methemoglobin content in the blood is 8-100% of the total hemoglobin content; or The collected ex vivo blood is treated with a gas treatment agent containing carbon monoxide, so that the content of carboxyhemoglobin in the ex vivo blood accounts for 25-100% of the total hemoglobin content.
[0013] According to the contrast agent preparation method of the embodiment of the present invention, optionally, the amount of blood collected from the body is a=1~200ml; and the processing time is t=1~30min.
[0014] According to the contrast agent preparation method of the embodiment of the present invention, optionally, the collected ex vivo blood is treated with a treatment agent containing nitric oxide gas or carbon monoxide gas, and the flow controller of the treatment agent module controls the output flow rate S of the gas to be V a / t, where V a is the volume of nitric oxide-containing gas or carbon monoxide-containing gas supplied by the treatment agent module to the blood container, V a =2×10 5 ×a×C b ; C b The concentration of nitric oxide or carbon monoxide supplied to the gas supply device.
[0015] According to the contrast agent preparation method of the embodiment of the present invention, optionally, when V a Larger than the upper limit V of the volume that the blood container can hold max When V a =V max , and adjust the concentration of nitric oxide or carbon monoxide supplied by the gas supply device C b =V a / (2×10 5 ×a).
[0016] According to one aspect of the present invention, there is provided a contrast agent prepared by the aforementioned contrast agent preparation device or contrast agent preparation method. Beneficial Effects
[0017] Compared with the prior art, the present invention has at least the following beneficial effects: The contrast agent preparation device of the present invention can process ex vivo blood by providing a gas treatment agent containing nitric oxide or carbon monoxide, thereby obtaining a contrast agent with methemoglobin or carboxyhemoglobin as a main component; the contrast agent preparation device of the present invention can process ex vivo blood with high efficiency and quickly obtain a contrast agent that meets clinical use.
[0018] By using the contrast agent preparation method of the present invention, a contrast agent with methemoglobin or carboxyhemoglobin as the main component can be prepared. The contrast agent is not metabolized by the liver and kidneys, has no hepatotoxicity and nephrotoxicity, will not be deposited in the brain, and will not cause nerve damage. Both methemoglobin and carboxyhemoglobin exist naturally in the normal human body, with a concentration between 0-2.5%. The methemoglobin content in smokers can reach 10-15%, and the carboxyhemoglobin content can reach 5-6.5%. Methemoglobin is metabolized by methemoglobin reductase (also known as cytochrome b5 reductase) in red blood cells, with a half-life of about 1 hour, and the half-life of carboxyhemoglobin is about 4-6 hours. The contrast agent prepared by the present invention has high safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 A schematic diagram of a contrast agent processing device according to an embodiment of the present invention; Figure 2 A schematic diagram of a gas supply device according to an embodiment of the present invention; In the figure, 100, treatment agent module; 110, gas supply device; 111, reaction chamber; 112, reaction medium; 113, electrode; 114, carrier gas inlet; 120, output pipeline; 130, flow controller; 200. Blood processing module; 210. Blood container; 220. Vibrating element. Implementation
[0020] It should be understood that, in the description of the present invention, the terms "center", "longitudinal", "lateral", "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom", "inside", "outside" and the like that may appear to indicate the orientation or positional relationship indicated are based on the orientation or positional relationship shown in the accompanying drawings, and are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, the terms "first", "second", etc. are only used for descriptive purposes, and cannot be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, features defined as "first", "second", etc. may explicitly or implicitly include one or more of the features. In the description of the present invention, unless otherwise specified, "multiple" means two or more.
[0021] It should be noted that in the description of the present invention, unless otherwise clearly specified and limited, the terms "disposed", "connected", and "connected" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two elements. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood by specific circumstances.
[0022] Oxygenated hemoglobin has weak diamagnetic properties because the bonding of oxygen results in a configuration without unpaired electrons around the heme iron. Methemoglobin (MHb) is the product of the oxidation of ferrous ions in hemoglobin to ferric ions. Methemoglobin changes the atomic structure and chemical bonds of the entire hemoglobin molecule because its ferric ions are different from the ferrous ions in normal hemoglobin. Water molecules can enter a position very close to the iron center, and the resulting complex is called hydrated methemoglobin. The process of "inner sphere water relaxation" occurs, which shortens the T1 value and is therefore a high signal on T1-weighted images. If MHb continues to be in the red blood cells, there will be a persistent local magnetic susceptibility effect, which can shorten the T2 / T2* value, so it is a low signal on the T2 / T2* weighted image; when the red blood cells rupture, the local T2 / T2* dephasing effect disappears, and MHb presents a high signal on the T2-weighted image. In addition, MHb is paramagnetic. MHb can change the relaxation time of T1, T2 and T2*, and can be used as a contrast agent for MRI. At the same time, because methemoglobin is a large molecule, it cannot penetrate into the tissue through the endothelial space. Therefore, after observing high or low perfusion signals on magnetic resonance, it can indicate whether the lesion is rich or poor in blood supply, avoiding the difficulty in diagnosing the blood supply characteristics of the lesion caused by the extravasation of traditional gadolinium into the extravascular space.
[0023] On the other hand, the affinity of carbon monoxide to hemoglobin is 200 to 300 times higher than that of oxygen to hemoglobin, so carbon monoxide is very easy to bind to hemoglobin, and hemoglobin is not easy to separate after binding with carbon monoxide, forming carboxy-haemoglobin (HbCO). When oxygenated hemoglobin in the blood is converted into carboxy-haemoglobin, the oxygen in hemoglobin is separated from the iron ions, and the conformation of hemoglobin changes, which prevents the surrounding water molecules from approaching the iron ions. Therefore, the carboxy-haemoglobin formed will have 4 unpaired electrons, so it is paramagnetic, can shorten the relaxation time of T1, T2 and T2*, and can be used as a contrast agent for MRI. At the same time, because carboxy-haemoglobin is a large molecule, it cannot penetrate into the tissue through the endothelial space of the blood vessel. Therefore, after observing high or low perfusion signals on magnetic resonance, it can indicate whether the lesion is rich or poor in blood supply, avoiding the difficulty in diagnosing the blood supply characteristics of the lesion caused by the extravasation of traditional gadolinium into the extravascular space.
[0024] Therefore, the present invention provides a contrast agent preparation device and method, which can quickly and effectively process ex vivo blood to prepare an ex vivo blood contrast agent whose main components are methemoglobin and / or carboxyhemoglobin.
[0025] Contrast agent preparation equipment
[0026] The contrast agent preparation device of this embodiment can convert part or all of the hemoglobin in the collected autologous blood into methemoglobin / carboxyhemoglobin.
[0027] like Figure 1 As shown, according to an embodiment of the present invention, the contrast agent preparation device includes at least the following modules: a treatment agent module 100, used to provide a treatment agent containing nitric oxide or carbon monoxide gas required for preparing the contrast agent; and a blood treatment module 200, used to use the treatment agent to process the collected ex vivo blood.
[0028] The composition of the contrast medium preparation apparatus is described in detail below.
[0029] Treatment agent module The treatment agent module 100 is used to provide a gas treatment agent required for preparing a contrast agent, such as a nitric oxide-containing gas or a carbon monoxide-containing gas.
[0030] To provide a gas treatment agent, the treatment agent module 100 of this embodiment may include: a gas supply device 110, used to pre-store or instantly prepare a gas containing nitric oxide or carbon monoxide; an output pipeline 120, which is connected to the gas supply device 110 and outputs a gas containing nitric oxide or carbon monoxide; and a flow controller 130, which is arranged on the output pipeline 120 and is used to control the output flow of the gas.
[0031] For the treatment agent module 100 that provides carbon monoxide-containing gas, the gas supply device 110 may be a gas storage cylinder to pre-store a certain concentration of carbon monoxide-containing gas. The gas supply device 110 may also be an instant preparation device to obtain the carbon monoxide-containing gas through an instant reaction, for example, through the following reaction: Use hot carbon to react with water vapor to produce carbon monoxide: C + H2O = CO↑ + H2↑; Formic acid is heated to 80°C under the action of concentrated H2SO4: HCOOH=H2O+CO↑; Carbon powder reduces CO2 at high temperature: C+CO2=2CO↑; At high temperature, carbon and iron oxide first undergo a reduction reaction to generate CO2, and the generated CO2 continues to react with carbon to generate CO: 3C+2Fe2O3=4Fe+3CO2↑C+CO2=2CO↑; Oxalate decomposition at high temperature: Na2C2O4==Na2CO3+CO↑; Thermal decomposition of nickel tetracarbonyl: {Ni(CO)4}=Ni+CO↑; CO is produced by electrolysis of CO2 at room temperature, and a catalyst is required for the reaction: CO2+H2O+2e–=CO+2OH–.
[0032] For the treatment agent module 100 that provides the nitric oxide-containing gas, the gas supply device 110 may be a gas storage cylinder to pre-store a certain concentration of nitric oxide-containing gas. The gas supply device 110 may also be an instant preparation device to obtain the nitric oxide-containing gas through an instant reaction, for example, through the following reaction: High voltage electric shock to the air produces nitric oxide: N2+O2⇋2NO; N2O4 is cracked to obtain NO2, which reacts with a reducing agent: N2O4(g)⇋2NO2(g) NO2+C6H8O6→NO+H2O+C6H6O5; Electrochemical catalysis to produce nitric oxide in a nitrite ion source: Cu(II)(L)+e→Cu(I)(L)Cu(I)(L)+NO2+2H + →Cu(II)(L)+NO+H2O; Chemical reaction to produce nitric oxide: 2RSNO→RS-RS+2NO; or 3NO2 2- +2H + →2NO+NO 3- +H2O.
[0033] Taking the electrochemical catalytic method as an example, the gas supply device 110 may include the following structure: The reaction chamber 111 has a gas region and a liquid region, wherein the liquid region is configured to accommodate a reaction medium 112, and the gas region is configured to accommodate a product gas including NO. The electrode 113 is in contact with the reaction medium 112. By applying a predetermined current or voltage to the electrode 113, NO gas can be generated in the reaction chamber 111. The carrier gas inlet 114 is used to introduce the carrier gas into the reaction medium 112 to purge and entrain the NO gas generated in the reaction medium 112. The carrier gas can be air, nitrogen, etc. The energy source is the electrode 113 to provide current or voltage, and the generated NO gas and the carrier gas are input into the output pipeline 120 through the gas outlet; specifically, the reaction medium 112 includes a buffer solution, A nitrite ion source and a catalyst, the catalyst includes a metal-ligand complex, the nitrite ion source includes one or more nitrites, for example, the composition of the reaction medium 112 can refer to Chinese Patent Publication No. CN114318357A, published on April 12, 2022, which discloses an electrolyte for achieving high-concentration NO output, an electrolytic cell using the same, and an electrolysis method, and the above contents are incorporated into this application by reference; a specific implementation structure of the electrochemical instant preparation device can refer to Chinese Patent Publication No. CN110831640A, published on February 21, 2020, which discloses a nitric oxide generation system for a gas delivery device, and the above contents are incorporated into this application by reference.
[0034] Blood processing module The blood processing module 200 is used to process the collected ex-vivo blood using a processing agent.
[0035] The blood processing module 200 may include the following structures: The blood container 210 is used to hold the collected ex-vivo blood. The blood container is configured to receive the nitric oxide-containing gas transmitted by the output pipeline. The blood container 210 can be a flexible material container such as a blood collection bag, or a hard container. The blood container 210 generally needs to have a sealing function to ensure that the gas does not escape to the outside after the nitric oxide-containing gas is introduced. It can be understood that the blood container 210 may not have a sealing function, and the blood container 210 may be placed in a closed processing chamber to perform the nitric oxide-passing operation; The vibrating member 220 is used to accommodate the blood container. The vibrating member is configured to vibrate the blood container so that the ex-vivo blood in the blood container 210 can be fully contacted with the nitric oxide-containing gas through the vibration.
[0036] In this embodiment, a sufficient amount of nitric oxide-containing gas may be pre-filled into a blood container 210, such as a blood collection bag, and after the blood container 210 is sealed, it is placed on the vibrating member 220 and starts vibrating; In this embodiment, the vibration action and the action of passing the nitric oxide gas can also be performed synchronously. For example, a purge component is provided, which is connected to the output pipeline 120. When in use, the purge component can be extended into the blood container 210 and located above the ex vivo blood. When the output pipeline 120 outputs the nitric oxide gas, the vibration component 220 is turned on to vibrate synchronously.
[0037] Through the structure of the blood processing module 200 of the present embodiment, hemoglobin in the ex vivo blood can be quickly and effectively converted into methemoglobin. Compared with the method of directly bubbling nitric oxide-containing gas into the blood, the structure of the present embodiment will not cause excessive foam in the blood, resulting in part of the blood being unusable; compared with the method of diffusing nitric oxide-containing gas through a membrane, the structure of the present embodiment has lower cost and higher processing efficiency.
[0038] Contrast agent preparation method
[0039] The contrast agent preparation method of this embodiment comprises at least the following steps: Collecting blood from the body; Providing a gas treatment agent containing nitric oxide or carbon monoxide required for preparing a contrast agent; Treating the collected blood with a nitric oxide-containing gas treatment agent until the methemoglobin content in the blood is 8-100% of the total hemoglobin content; or The collected ex vivo blood is treated with a gas treatment agent containing carbon monoxide, so that the content of carboxyhemoglobin in the ex vivo blood accounts for 25-100% of the total hemoglobin content.
[0040] Those skilled in the art should understand that these steps can correspond one by one to the various modules of the contrast agent preparation device described above. Nevertheless, such a correspondence is not necessary. In other words, the execution of each step in the contrast agent preparation method does not have to rely on the implementation of each module in the contrast agent preparation device. The scope of protection of the present invention shall be subject to the limitations of the claims, and the description in the specification is only used to provide one or more feasible specific embodiments and should not be interpreted as limiting the scope of protection of the present invention.
[0041] The collection of ex vivo blood can be achieved by a conventional blood collection device, which will not be elaborated here. The ex vivo blood can be the patient's autologous blood and / or blood that meets the conditions for allogeneic blood transfusion. For example, the ex vivo blood can be autologous blood collected from the patient's vein.
[0042] The amount of ex vivo blood usually collected is a=1~200ml, preferably, it can be 5~200ml, and more preferably, it can be 5~50ml; the amount of ex vivo blood collected can be determined based on the patient's weight, such as by the formula a=(0.01ml / kg~2ml / kg)*W, W is the patient's weight in kilograms (kg). It should be noted here that the approved use range of many Gd enhancers is 0.025mmol / kg~0.1mmol / kg, and 0.1mmol / kg is commonly used, corresponding to a volume of 0.01-0.2ml / kg. Gd and methemoglobin are both paramagnetic materials, and the paramagnetic strength is proportional to the square of the number of unpaired electrons. Gd 2+ There are 7 unpaired electrons, Fe 3+ There are 5 unpaired electrons, and the paramagnetic strength ratio is about 2:1. The Fe content in adult blood hemoglobin is about 8~16mmol / L. 2+ For the same paramagnetic strength, the blood volume of 100% methemoglobin transfusion needs to reach 12.5~25ml / kg. Gd enhancer will leak out of the blood vessels and it is difficult to maintain the intravascular concentration. The contrast agent in this scheme only exists in the blood vessels and bleeding points and is only used for blood vessel and bleeding imaging. In terms of vascular imaging, the effective concentration is higher than Gd, and a variety of MRA imaging methods can be used to further improve the signal-to-noise ratio. Therefore, the enhancer in this scheme only needs to reach about 5% of the paramagnetic strength of the Gd enhancer before the bolus injection, that is, the volume of autologous blood injected is between 0.01ml / kg~2ml / kg, that is, the blood collection volume a is (0.01ml / kg~2ml / kg)*W.
[0043] At the same time, it can be adjusted according to the patient's weight and smoking status. The volume of human blood accounts for about 7-8% of body weight. 200ml is the upper limit of blood drawing for patients weighing 100kg or more. The blood drawn is less than 3% of the patient's whole blood, and it is returned after processing without safety risks. Less than 5ml is difficult to operate (preparation, bolus injection, etc.).
[0044] The collected ex vivo blood is treated using a nitric oxide-containing gas treatment agent. The specific treatment method may be: introducing nitric oxide-containing gas into the blood and vibrating the blood so that the blood can be fully in contact with the nitric oxide-containing gas. The above method may be achieved by the contrast agent preparation device of this embodiment or by other structures.
[0045] The collected ex vivo blood is treated using a carbon monoxide-containing gas treatment agent. The specific treatment method may be: introducing carbon monoxide-containing gas into the blood and vibrating the blood so that the blood can be fully in contact with the carbon monoxide-containing gas. The above method may be achieved by the contrast agent preparation device of this embodiment or by other structures.
[0046] After a certain period of ventilation and / or vibration, the content of methemoglobin / carboxyhemoglobin in the blood will gradually increase, and the preparation is completed when the content of methemoglobin in the ex vivo blood accounts for 8-100% of the total hemoglobin content or the content of carboxyhemoglobin in the ex vivo blood accounts for 25-100% of the total hemoglobin content.
[0047] The expected range of methemoglobin concentration is related to the application and the patient's smoking status. In the embodiment of the present invention, the expected range is set between 8 and 100%. The methemoglobin content in a normal human body accounts for 0.2 to 2% of the hemoglobin content, and the methemoglobin content in heavy smokers can be as high as 3 to 5%. Since the concentration of methemoglobin in blood outside the body is positively correlated with the T1-weighted signal intensity outside the body, the T1-weighted signal intensity of methemoglobin accounting for 8% is increased by 10%, 20%, and 40% compared with 2%, 1%, and 0%, respectively. Considering the large noise in the body, the difference in methemoglobin content in the human body, and the blood is in a flowing state, the MRI signal enhancement ratio is much lower than that in a static state, so it is considered that the minimum content that can be used for imaging is 8%. In addition, considering that smokers have a higher methemoglobin background, the concentration used for imaging needs to be increased. Some applications hope to observe new small blood vessels and tiny vascular network structures. The stronger the signal per unit volume, the better, and the higher the signal-to-noise ratio, the better, so the upper limit of the content is 100%.
[0048] Furthermore, in this embodiment, the time for processing the ex vivo blood is t=1~30min, and the flow rate of the input blood container 210 is controlled by the flow controller of the treatment agent module 100; generally, the longer the time for processing the ex vivo blood is, the more helpful it is to increase the content of methemoglobin or carboxyhemoglobin in the blood, but if the processing time is too long, on the one hand, it will cause precipitation after the peak value of the content increase, and the content will decrease instead. On the other hand, if the processing time is too long, in actual clinical application, it will cause patients to wait too long, reducing the clinical experience.
[0049] Furthermore, in this embodiment, the flow controller controls the output flow rate S of the gas = V a / t, where V a is the volume of nitric oxide-containing gas or carbon monoxide-containing gas supplied by the treatment agent module to the blood container, V a =2×10 5 ×a×C b ; C bThe concentration of nitric oxide or carbon monoxide supplied by the gas supply device can be regarded as a known value. Taking nitric oxide supply as an example, in some cases, the concentration of nitric oxide supplied by the gas supply device is constant, such as using a gas cylinder for supply. In other cases, the concentration of nitric oxide supplied by the gas supply device can also be adjusted. For example, the equipment used in the electrochemical catalytic method described above in this embodiment can control the output nitric oxide concentration by adjusting the current / voltage supplied to the electrode 113.
[0050] Furthermore, in some cases, in order to convert the hemoglobin in the ex vivo blood into the required amount of methemoglobin, a sufficient amount of gas needs to be introduced. Considering that the pressure that some blood containers 210 can withstand is limited, when the concentration of supplied nitric oxide is low, it may be necessary to transmit a larger volume of nitric oxide-containing gas, or supply it in batches. In this way, it is easy to reach the upper limit of the pressure of the blood container 210 and cause the container to rupture. The batch method will increase the processing time. Usually, clinical experience is cross-cutting. Therefore, when the volume V of the nitric oxide-containing gas supplied by the treatment agent module to the blood container is calculated, a Greater than the upper limit V of the volume that the blood container 210 can hold max When (V max It is usually related to the material and structure of the blood container 210. Usually, when the blood container 210 is selected, this value can be obtained by testing, so it can be regarded as a known value). a =V max , to prevent the subsequent transmission of nitric oxide from exceeding the upper limit of the blood container 210, and to improve the processing efficiency, the concentration of nitric oxide supplied by the gas supply device is adjusted, C b =V a / (2×10 5 ×a).
[0051] The following shows that the contrast agent preparation device of the present invention is combined with the contrast agent preparation method of the present invention to conduct a sheep blood test, using a nitric oxide-containing gas treatment agent, and the data obtained are as follows: Application Examples Blood volume collected (ml) Nitric oxide gas concentration (ppm) Transmission gas volume (ml) Flow rate (ml / min) Processing time (min) Methemoglobin concentration after treatment (%) Application Example 1 10 200 250 50 5 0.4 Application Example 2 10 3000 250 50 5 6.7 Application Example 3 10 50000 250 50 5 93.7 Application Example 4 10 50000 250 50 10 94.1 Application Example 5 10 50000 250 50 35 96.4 The following shows that the contrast agent preparation device of the present invention is combined with the contrast agent preparation method of the present invention to perform a sheep blood test, using a carbon monoxide-containing gas treatment agent, and the data obtained are as follows: Application Examples Blood volume collected (ml) Nitric oxide gas concentration (ppm) Transmission gas volume (ml) Flow rate (ml / min) Processing time (min) Carboxyhemoglobin concentration after treatment (%) Application Example 1 10 50000 250 50 30 93.6 Application Example 2 10 50000 250 50 35 91.2 Application Example 3 10 50000 250 50 5 13.1 The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.
Claims
1. A contrast agent preparation device, characterized in that: include: A treatment agent module, used for providing a gas treatment agent containing nitric oxide or carbon monoxide required for preparing a contrast agent; The blood processing module is used to process the collected ex-vivo blood using a processing agent.
2. A contrast agent preparation device according to claim 1, characterized in that: The treatment agent module comprises: A gas supply device for pre-storing or instant preparation of gas containing nitric oxide or carbon monoxide; An output pipeline connected to the gas supply device to output the gas containing nitric oxide or carbon monoxide; The flow controller is arranged on the output pipeline and is used to control the output flow of the gas.
3. A contrast agent preparation device according to claim 2, characterized in that: The gas supply device is a nitric oxide supply device, comprising: A reaction chamber, a reaction medium contained in the reaction chamber, a plurality of electrodes arranged in the reaction medium, a carrier gas inlet for introducing a carrier gas into the reaction medium, a gas outlet for outputting a product gas, and an energy source acting on the plurality of electrodes.
4. A contrast agent preparation device according to claim 3, characterized in that: The blood processing module comprises: A blood container, which is used to hold the collected ex-vivo blood, and the blood container is configured to receive the nitric oxide-containing gas transmitted by the output pipeline; A vibrating member is used for accommodating a blood container, wherein the vibrating member is configured to vibrate the blood container.
5. A contrast agent preparation device according to claim 4, characterized in that: The blood processing module further comprises: A purge member, one end of which is connected to the output pipeline of the treatment agent module and the other end of which is located above the ex vivo blood; The blood treatment module is configured to allow the nitric oxide-containing gas treatment agent to be swept from above the ex vivo blood, while the vibration element applies vibration to the ex vivo blood, so that the ex vivo blood contacts the nitric oxide-containing gas treatment agent.
6. A contrast agent preparation device according to claim 4, characterized in that: The blood treatment module is configured such that after a sufficient amount of the nitric oxide-containing gas treatment agent is pre-filled into the blood container, the vibrator applies vibration to the ex vivo blood so that the ex vivo blood contacts the nitric oxide-containing gas treatment agent.
7. A method for preparing a contrast agent, characterized in that: The steps include: Collecting blood from the body; Providing a gas treatment agent containing nitric oxide or carbon monoxide required for preparing a contrast agent; Treating the collected blood with a nitric oxide-containing gas treatment agent until the methemoglobin content in the blood is 8-100% of the total hemoglobin content; or The collected ex vivo blood is treated with a carbon monoxide-containing gas treatment agent until the carboxyhemoglobin content in the ex vivo blood accounts for 25-100% of the total hemoglobin content.
8. A method for preparing a contrast agent according to claim 7, characterized in that: The amount of blood collected from the body is a = 1~200ml; Processing time t=1~30min.
9. A method for preparing a contrast agent according to claim 8, characterized in that: The collected blood is treated with a treatment agent containing nitric oxide or carbon monoxide. The flow controller of the treatment agent module controls the output flow rate S=V a / t, where V a is the volume of nitric oxide-containing gas or carbon monoxide-containing gas supplied by the treatment agent module to the blood container, V a =2×10 5 ×a×C b ; C b The concentration of nitric oxide or carbon monoxide supplied to the gas supply device.
10. A method for preparing a contrast agent according to claim 9, characterized in that: When V a Larger than the upper limit V of the volume that the blood container can hold max When V a =V max , and adjust the concentration of nitric oxide or carbon monoxide supplied by the gas supply device C b =V a / (2×10 5 ×a).
11. A contrast agent, characterized in that: The contrast agent is prepared by the contrast agent preparation device according to claims 1 to 6; or The contrast agent is prepared by the contrast agent preparation method according to claims 7 to 10.
